Oryzon Genomics S.A. (ORYZF)
| Market Cap | 290.97M +205.2% |
| Revenue (ttm) | 8.63M -45.5% |
| Net Income | -3.23M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 115.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,200 |
| Average Volume | 2,577 |
| Open | 3.600 |
| Previous Close | 3.360 |
| Day's Range | 3.600 - 3.600 |
| 52-Week Range | 1.575 - 4.375 |
| Beta | 0.36 |
| RSI | 58.47 |
| Earnings Date | Feb 27, 2026 |
About Oryzon Genomics
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is... [Read more]
Financial Performance
In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.
Financial StatementsNews
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A.
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today a...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
MADRID and CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, to...
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics...
ORYZON to Participate in Upcoming Events in November
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics,...
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigene...
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, toda...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A.
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigene...
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, to...
ORYZON to Host Virtual KOL Event on July 9, 2025
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD To discuss the unmet medical need in Borderline Personality ...
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, an...
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
MADRID and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, ann...
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A.
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develo...
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
MADRID and CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop thera...
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for disea...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
MADRID and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
MADRID and CAMBRIDGE, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting
MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
MADRID and CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therap...
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
MADRID and CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop thera...